

CITATION REPORT

List of articles citing

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice

DOI: 10.1016/j.cell.2015.06.003
Cell, 2015, 161, 1505-15.

Source: <https://exaly.com/paper-pdf/62068276/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
224	Exceptional Antibodies Produced by Successive Immunizations. 2015 , 13, e1002321		
223	Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens. 2015 , 2015, 156241		51
222	HIV-specific B cell response in patients with broadly neutralizing serum activity. 2015 , 350, 1175		2
221	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. <i>Cell</i> , 2015 , 163, 1702-15	56.2	251
220	Origins of a Vaccine-Induced, Human Anti-HIV-1 Antibody. 2015 , 2, 632-3		
219	HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. 2015 , 349, 156-61		264
218	PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey. 2015 , 349, 386-7		20
217	SOFT ROBOTICS. A 3D-printed, functionally graded soft robot powered by combustion. 2015 , 349, 161-5		608
216	HIV. The modern era of HIV-1 vaccine development. 2015 , 349, 139-40		28
215	Tailored immunogens for rationally designed antibody-based HIV-1 vaccines. 2015 , 36, 437-9		6
214	Immune correlates of vaccine protection against HIV-1 acquisition. 2015 , 7, 310rv7		142
213	Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. <i>Cell</i> , 2015 , 163, 1095-1107	56.2	103
212	Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. 2015 , 89, 10383-98		105
211	Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization. 2015 , 89, 12501-12		67
210	Common Characteristics of HIV-Neutralizing Antibodies with a Fondness for Sugars. 2015 , 43, 837-40		
209	Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. 2015 , 486, 116-20		32
208	Structural basis for germline antibody recognition of HIV-1 immunogens. 2016 , 5,		48

207	Recent update in HIV vaccine development. 2016 , 5, 6-11		24
206	Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. 2016 , 12, e1005815		76
205	The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype. 2016 , 32, 1135-1142		10
204	Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. 2016 , 7, 10618		117
203	Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. 2016 , 7, 12041		101
202	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. 2016 , 24, 2021-2032		28
201	Naturally Occurring Fc-Dependent Antibody From HIV-Seronegative Individuals Promotes HIV-Induced IFN- β Production. 2016 , 6, 37493		1
200	Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. <i>Journal of Experimental Medicine</i> , 2016 , 213, 469-81	16.6	210
199	Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory. 2016 , 44, 769-81		79
198	Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. 2016 , 213, 1946-54		8
197	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. <i>Cell</i> , 2016 , 165, 813-26	56.2	301
196	Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. <i>Annual Review of Immunology</i> , 2016 , 34, 635-59	34.7	366
195	Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. 2016 , 90, 10220-10235		21
194	Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. 2016 , 353, 1557-1560		106
193	Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. <i>Cell</i> , 2016 , 166, 1445-1458.e12	56.2	204
192	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. <i>Cell</i> , 2016 , 166, 1471-1484.e18	56.2	132
191	Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. 2016 , 113, E6639-E6648		164
190	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. 2016 , 45, 483-496		232

189	Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. 2016 , 90, 9224-36		22
188	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. 2016 , 16, 2327-38		163
187	Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. 2016 , 3, 16068		41
186	Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. 2016 , 23, 906-915		143
185	Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. 2016 , 11, 1908-1923		83
184	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. <i>Cell</i> , 2016 , 166, 609-623	56.2	215
183	Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. 2016 , 8, 336ra62		65
182	Structural biology: Variability without change. 2016 , 1, 16218		
181	Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors. 2016 , 17, 1560-1570		20
180	Optimal immunization cocktails can promote induction of broadly neutralizing Abs against highly mutable pathogens. 2016 , 113, E7039-E7048		37
179	Approaches to the induction of HIV broadly neutralizing antibodies. 2016 , 11, 569-575		12
178	Report of the Cent Gardes HIV Vaccines Conference. Part 1: The antibody response; Fondation Mérieux Conference Center, Veyrier-du-Lac, France, 25-27 October 2015. 2016 , 34, 3557-61		1
177	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. 2016 , 113, E3413-22		132
176	Universal influenza vaccine design: directing the antibody repertoire. 2016 , 11, 451-467		2
175	Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets. 2016 , 12, 2640-2648		23
174	HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. 2016 , 15, 349-65		38
173	Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. 2016 , 351, 1043-8		319
172	HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. 2016 , 351, 1458-63		266

171	High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. 2016 , 196, 3729-43		24
170	HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. 2016 , 37, 221-232		78
169	CXCL13 is a plasma biomarker of germinal center activity. 2016 , 113, 2702-7		204
168	HIV-Host Interactions: Implications for Vaccine Design. 2016 , 19, 292-303		108
167	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016 , 165, 449-63	56.2	209
166	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. 2016 , 23, 81-90		126
165	In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates. 2016 , 11, 193-213		26
164	Current views on the potential for development of a HIV vaccine. 2017 , 17, 295-303		20
163	Native-like Env trimers as a platform for HIV-1 vaccine design. 2017 , 275, 161-182		166
162	Identification and specificity of broadly neutralizing antibodies against HIV. 2017 , 275, 11-20		155
161	Evolution of B cell analysis and Env trimer redesign. 2017 , 275, 183-202		18
160	The quest for an antibody-based HIV vaccine. 2017 , 275, 5-10		71
159	Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1. 2017 , 275, 108-128		26
158	Germline-targeting immunogens. 2017 , 275, 203-216		62
157	Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. 2017 , 275, 89-107		24
156	What Are the Most Powerful Immunogen Design Vaccine Strategies? A Structural Biologist's Perspective. 2017 , 9,		19
155	Particle-based delivery of the HIV envelope protein. 2017 , 12, 265-271		13
154	Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach. 2017 , 46, 804-817.e7		62

153	Guiding the long way to broad HIV neutralization. 2017 , 12, 257-264		10
152	Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity. 2017 , 292, 10197-10219		16
151	Protein design: from computer models to artificial intelligence. 2017 , 7, e1318		15
150	How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. 2017 , 12, 229-240		44
149	Progress in HIV-1 antibody research using humanized mice. 2017 , 12, 285-293		10
148	Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. 2017 , 91,		19
147	Progress toward active or passive HIV-1 vaccination. <i>Journal of Experimental Medicine</i> , 2017 , 214, 3-16	16.6	94
146	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. <i>Journal of Experimental Medicine</i> , 2017 , 214, 2573-2590	16.6	100
145	Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development. 2017 , 47, 524-537.e3		29
144	The microanatomic segregation of selection by apoptosis in the germinal center. 2017 , 358,		114
143	Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins. 2017 , 9, 1052-1064		7
142	Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. 2017 , 21, 2992-3002		38
141	HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage. 2017 , 47, 990-1003.e9		71
140	Identification and characterization of a naturally occurring, efficiently cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with properties comparable to membrane-bound BG505. 2017 , 510, 22-28		7
139	A Novel Rabies Vaccine Expressing CXCL13 Enhances Humoral Immunity by Recruiting both T Follicular Helper and Germinal Center B Cells. 2017 , 91,		21
138	Natural infection as a blueprint for rational HIV vaccine design. 2017 , 13, 229-236		3
137	Targeted Elimination of Immunodominant B Cells Drives the Germinal Center Reaction toward Subdominant Epitopes. 2017 , 21, 3672-3680		17
136	Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination. 2017 , 51, 819-829		1

135	Mechanisms of Adaptive Immunity to Porcine Reproductive and Respiratory Syndrome Virus. 2017 , 9,		36
134	Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success. <i>Frontiers in Immunology</i> , 2016 , 7, 661	8.4	8
133	The Antibody-Secreting Cell Response to Infection: Kinetics and Clinical Applications. <i>Frontiers in Immunology</i> , 2017 , 8, 630	8.4	38
132	Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem. 2017 , 134, 235-352		7
131	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. 2017 , 13, e1006148		36
130	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. 2017 , 8, 1732		52
129	Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses. 2017 , 14, 55		13
128	Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. 2018 , 115, 4743-4748		53
127	Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. 2018 , 48, 133-146.e6		173
126	What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Lessons from the Antibody Response to HIV-1. 2018 , 10,		19
125	Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. 2018 , 293, 1688-1701		26
124	EDiP: the Epitope Dilution Phenomenon. Lessons learnt from a malaria vaccine antigen and its applicability to polymorphic antigens. 2018 , 17, 13-21		3
123	Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto- and heterologous viruses. 2018 , 293, 830-846		10
122	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. 2018 , 14, e1007431		20
121	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. 2018 , 49, 1162-1174.e8		32
120	HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth. 2018 , 15, 74		22
119	Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. 2018 , 9, 4136		6
118	Recent progress in broadly neutralizing antibodies to HIV. 2018 , 19, 1179-1188		186

117	When designing vaccines, consider the starting material: the human B cell repertoire. 2018 , 53, 209-216	44
116	Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. 2018 , 15, 61	41
115	The Neutralizing Antibody Response to the HIV-1 Env Protein. 2018 , 16, 21-28	20
114	One-step generation of monoclonal B cell receptor mice capable of isotype switching and somatic hypermutation. <i>Journal of Experimental Medicine</i> , 2018 , 215, 2686-2695	16.6 9
113	Strategies for a multi-stage neutralizing antibody-based HIV vaccine. 2018 , 53, 143-151	55
112	HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. 2018 , 48, 855-871	180
111	Role of framework mutations and antibody flexibility in the evolution of broadly neutralizing antibodies. 2018 , 7,	44
110	The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. 2018 , 10,	62
109	Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design. 2018 , 15, 53	15
108	Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. 2018 , 49, 301-311.e5	70
107	Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. 2018 , 49, 288-300.e8	110
106	Targeting Glycans on Human Pathogens for Vaccine Design. 2020 , 428, 129-163	3
105	Immune Correlate-Guided HIV Vaccine Design. 2018 , 24, 25-33	34
104	Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine. 2018 , 1075, 73-95	9
103	Bone marrow stem cells to destroy circulating HIV: a hypothetical therapeutic strategy. 2018 , 25, 3	2
102	Exploiting glycan topography for computational design of Env glycoprotein antigenicity. <i>PLoS Computational Biology</i> , 2018 , 14, e1006093	5 14
101	One-step CRISPR/Cas9 method for the rapid generation of human antibody heavy chain knock-in mice. 2018 , 37,	20
100	Human Immunodeficiency Virus Vaccines. 2018 , 400-429.e25	

99	Exploration of HIV-1 fusion peptide-antibody VRC34.01 binding reveals fundamental neutralization sites. 2019 , 21, 18569-18576		3
98	Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan. 2019 , 51, 141-154.e6		38
97	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. <i>Cell</i> , 2019 , 178, 567-584.e19	56.2	64
96	Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2331-2347	16.6	9
95	Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2316-2330	16.6	12
94	Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire. 2019 , 292, 24-36		7
93	Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice. 2019 , 47, 247-256		4
92	Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus. 2019 , 51, 735-749.e8		37
91	Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles. 2019 , 27, 2080-2090		27
90	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. 2019 , 50, 1513-1529.e9		39
89	Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. 2019 , 17, e3000328		24
88	The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. 2019 , 27, 2426-2441.e6		20
87	Antibody responses to viral infections: a structural perspective across three different enveloped viruses. 2019 , 4, 734-747		89
86	B Cells Carrying Antigen Receptors Against Microbes as Tools for Vaccine Discovery and Design. 2020 , 428, 165-180		
85	Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens. 2019 , 108, 2264-2277		11
84	Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. 2019 , 294, 5616-5631		14
83	Cis- and trans-factors affecting AID targeting and mutagenic outcomes in antibody diversification. 2019 , 141, 51-103		13
82	HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. <i>Journal of Experimental Medicine</i> , 2019 , 216, 1301-1310	16.6	36

81	NFPws: a web server for delineating broadly neutralizing antibody specificities from serum HIV-1 neutralization data. 2019 , 35, 3502-3504		3
80	Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design. 2019 , 14, 294-301		5
79	Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. 2019 , 29, 3060-3072.e7		11
78	Strategies for inducing effective neutralizing antibody responses against HIV-1. 2019 , 18, 1127-1143		17
77	Coevolution of HIV-1 and broadly neutralizing antibodies. 2019 , 14, 286-293		6
76	Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. 2019 , 93,		11
75	Restricted Clonality and Limited Germinal Center Reentry Characterize Memory B Cell Reactivation by Boosting. <i>Cell</i> , 2020 , 180, 92-106.e11	56.2	94
74	HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors. 2020 , 53, 840-851.e6		8
73	Antibody-guided structure-based vaccines. 2020 , 50, 101428		16
72	Optimizing immunization protocols to elicit broadly neutralizing antibodies. 2020 , 117, 20077-20087		14
71	Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates. <i>Cell</i> , 2020 , 183, 1298-1311.e11	56.2	59
70	Vaccination Strategies Against Highly Variable Pathogens. 2020 ,		
69	B cells expressing authentic naïve human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. 2020 , 117, 22920-22931		20
68	Efficiently cleaved HIV-1 envelopes: can they be important for vaccine immunogen development?. 2020 , 8, 2515135520957763		1
67	Influenza vaccination strategies targeting the hemagglutinin stem region. 2020 , 296, 132-141		6
66	HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice. 2020 , 204, 1543-1561		1
65	Eliciting B cell immunity against infectious diseases using nanovaccines. 2021 , 16, 16-24		41
64	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations.		

63	▣▣▣Rapid Selection of HIV Envelopes that Bind to Neutralizing Antibody B Cell Lineage Members with Functional Improbable Mutations.	0
62	HIV vaccinology: 2021 update. 2021 , 51, 101470	3
61	Design of immunogens to elicit broadly neutralizing antibodies against HIV targeting the CD4 binding site. 2021 , 118,	4
60	Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. 2021 , 54, 324-339.e8	15
59	HIV mRNA Vaccines-Progress and Future Paths. 2021 , 9,	18
58	Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody. 2021 , 118,	7
57	Roadmap on biology in time varying environments. 2021 , 18,	2
56	Mechanisms underlying vaccination protocols that may optimally elicit broadly neutralizing antibodies against highly mutable pathogens. 2021 , 103, 052408	3
55	Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies. 2021 , 35, 109084	1
54	Sequencing, cloning, and antigen binding analysis of monoclonal antibodies isolated from single mouse B cells. 2021 , 2, 100389	1
53	Germinal center-dependent and -independent memory B cells produced throughout the immune response. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6 14
52	In vitro affinity maturation of broader and more-potent variants of the HIV-1-neutralizing antibody CAP256-VRC26.25. 2021 , 118,	2
51	Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application. <i>Frontiers in Immunology</i> , 2021 , 12, 697683	8.4 1
50	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. 2021 , 36, 109561	2
49	Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain.	0
48	Multiscale affinity maturation simulations to elicit broadly neutralizing antibodies against HIV.	1
47	Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward. 2021 , 9,	1
46	High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination. 2021 , 10,	3

45	CHAPTER 11:Targeting Glycans of HIV Envelope Glycoproteins for Vaccine Design. 2017 , 300-357		3
44	Modulating the quantity of HIV Env-specific CD4 T cell help promotes rare B cell responses in germinal centers. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	12
43	Optimizing immunization protocols to elicit broadly neutralizing antibodies.		2
42	B cells expressing authentic naive human VRC01-class BCRs can be primed and recruited to germinal centers in multiple independent mouse models.		1
41	Mechanisms underlying vaccination protocols that may optimally elicit broadly neutralizing antibodies against highly mutable pathogens.		1
40	High-resolution mapping of the neutralizing and binding specificities of polyclonal rabbit serum elicited by HIV Env trimer immunization.		0
39	Functional Improbable Antibody Mutations Critical for HIV Broadly Neutralizing Antibody Development.		1
38	Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen binding affinity.		0
37	Harnessing the protective potential of HIV-1 neutralizing antibodies. 2016 , 5,		4
36	Likelihood-Based Inference of B Cell Clonal Families. <i>PLoS Computational Biology</i> , 2016 , 12, e1005086	5	53
35	HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. 2017 , 12, e0181886		13
34	Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. 2016 , 12, e1005864		101
33	Multiplexed CRISPR/CAS9-mediated engineering of pre-clinical mouse models bearing native human B cell receptors. 2021 , 40, e105926		9
32	Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core. 2018 , 7,		19
31	A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. 2020 , 9,		6
30	One-step generation of monoclonal B cell receptor mice capable of class switch recombination and somatic hypermutation.		
29	Chimpanzee SIV Envelope trimer: structure and deployment as an HIV vaccine template.		1
28	Antigen-specific humoral immune responses by CRISPR/Cas9-edited B cells.		

27	A Broadly Neutralizing Macaque Monoclonal Antibody Against the HIV-1 V3-Glycan Patch.		
26	Spatially regulated protease activity in lymph nodes renders B cell follicles a sanctuary for retention of intact antigens.		0
25	Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. 2021 , 24 Suppl 7, e25831		5
24	Public Immunity: Evolutionary Spandrels for Pathway-Amplifying Protective Antibodies.. <i>Frontiers in Immunology</i> , 2021 , 12, 708882	8.4	0
23	VDJ Gene Usage in IgM Repertoires of Rhesus and Cynomolgus Macaques.. <i>Frontiers in Immunology</i> , 2021 , 12, 815680	8.4	1
22	Germinal Centers.. <i>Annual Review of Immunology</i> , 2022 ,	34.7	14
21	HIV-1 Vpu restricts Fc-mediated effector functions in vivo.		0
20	Identification of CDRH3 Loops in the Naive B Cell Receptor Repertoire that Can Be Engaged by Candidate Immunogens.		
19	Multiscale affinity maturation simulations to elicit broadly neutralizing antibodies against HIV.. <i>PLoS Computational Biology</i> , 2022 , 18, e1009391	5	0
18	Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain.. <i>Science Advances</i> , 2022 , 8, eabm3948	14.3	
17	Highly protective antimalarial antibodies via precision library generation and yeast display screening. <i>Journal of Experimental Medicine</i> , 2022 , 219,	16.6	1
16	Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein. 2022 , 13,		1
15	CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals.		0
14	Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice. 2022 ,		0
13	Use of Transient Transfection for cGMP Manufacturing of eOD-GT8 60mer, a Self-Assembling Nanoparticle Germline-Targeting HIV-1 Vaccine Candidate.		1
12	Humanized V(D)J-rearranging and TdT-expressing Mouse Vaccine Models with Physiological HIV-1 Broadly Neutralizing Antibody Precursors.		0
11	Adjuvants influence the maturation of VRC01-like antibodies during immunization. 2022 , 105473		0
10	Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates.		0

- 9 HIV-1 Vpu restricts Fc-mediated effector functions in vivo. **2022**, 41, 111624 0
- 8 Continuous germinal center invasion contributes to the diversity of the immune response. **2022**, 1
- 7 Vaccination induces HIV broadly neutralizing antibody precursors in humans. **2022**, 378, 5
- 6 Low protease activity in B cell follicles promotes retention of intact antigens after immunization. **2023**, 379, 3
- 5 Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. **2023**, 101003 0
- 4 Application of germline antibody features to vaccine development, antibody discovery, antibody optimization and disease diagnosis. **2023**, 65, 108143 0
- 3 CD4 binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wild-type animals. **2023**, 8, 0
- 2 Vaccine induction of CD4-mimicking broadly neutralizing antibody precursors in macaques. 0
- 1 Adjuvants influence the maturation of VRC01-like antibodies during immunization. 0